• Je něco špatně v tomto záznamu ?

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

A. Poveda, S. Lheureux, N. Colombo, D. Cibula, K. Lindemann, J. Weberpals, M. Bjurberg, A. Oaknin, M. Sikorska, A. González-Martín, R. Madry, MJR. Pérez, J. Ledermann, R. Davidson, C. Blakeley, J. Bennett, A. Barnicle, E. Škof

. 2022 ; 164 (3) : 498-504. [pub] 20220119

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019284

OBJECTIVE: The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (gBRCAm) who had platinum-sensitive relapsed ovarian cancer (PSROC) and had received ≥2 previous lines of platinum-based chemotherapy. METHODS: In this single-arm, open-label, international study, patients who had responded to platinum-based chemotherapy received maintenance olaparib tablets (300 mg twice daily) until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed progression-free survival (PFS) (modified RECIST version 1.1). A key secondary endpoint was PFS by homologous recombination deficiency (HRD) and somatic BRCAm (sBRCAm) status. The primary analysis of PFS was planned for 18 months after the last patient received their first dose. RESULTS: Two hundred and seventy-nine patients were enrolled and received olaparib. At data cutoff (October 2, 2020), 210 PFS events had occurred (75.3% maturity) and median PFS was 9.2 months (95% confidence interval [CI], 7.6-10.9) in the overall population. At 12 and 18 months, 38.5% and 24.3% of patients were progression-free, respectively. In the predefined biomarker subgroups, median PFS was 16.4, 11.1, 9.7, and 7.3 months in sBRCAm, HRD-positive including sBRCAm, HRD-positive excluding sBRCAm, and HRD-negative patients, respectively. The most common treatment-emergent adverse events (TEAEs) were nausea (48.4%) and fatigue/asthenia (44.1%). TEAEs led to dose interruption, dose reduction, and treatment discontinuation in 47.0%, 22.6%, and 7.5% of patients, respectively. CONCLUSION: Maintenance olaparib demonstrated clinical benefit in patients without a gBRCAm, and across all subgroups, compared with historical placebo controls. There were no new safety signals.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019284
003      
CZ-PrNML
005      
20220804135516.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ygyno.2021.12.025 $2 doi
035    __
$a (PubMed)35063276
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Poveda, A $u Initia Oncology, Valencia, Spain. Electronic address: apoveda@initiaoncologia.com
245    10
$a Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis / $c A. Poveda, S. Lheureux, N. Colombo, D. Cibula, K. Lindemann, J. Weberpals, M. Bjurberg, A. Oaknin, M. Sikorska, A. González-Martín, R. Madry, MJR. Pérez, J. Ledermann, R. Davidson, C. Blakeley, J. Bennett, A. Barnicle, E. Škof
520    9_
$a OBJECTIVE: The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (gBRCAm) who had platinum-sensitive relapsed ovarian cancer (PSROC) and had received ≥2 previous lines of platinum-based chemotherapy. METHODS: In this single-arm, open-label, international study, patients who had responded to platinum-based chemotherapy received maintenance olaparib tablets (300 mg twice daily) until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed progression-free survival (PFS) (modified RECIST version 1.1). A key secondary endpoint was PFS by homologous recombination deficiency (HRD) and somatic BRCAm (sBRCAm) status. The primary analysis of PFS was planned for 18 months after the last patient received their first dose. RESULTS: Two hundred and seventy-nine patients were enrolled and received olaparib. At data cutoff (October 2, 2020), 210 PFS events had occurred (75.3% maturity) and median PFS was 9.2 months (95% confidence interval [CI], 7.6-10.9) in the overall population. At 12 and 18 months, 38.5% and 24.3% of patients were progression-free, respectively. In the predefined biomarker subgroups, median PFS was 16.4, 11.1, 9.7, and 7.3 months in sBRCAm, HRD-positive including sBRCAm, HRD-positive excluding sBRCAm, and HRD-negative patients, respectively. The most common treatment-emergent adverse events (TEAEs) were nausea (48.4%) and fatigue/asthenia (44.1%). TEAEs led to dose interruption, dose reduction, and treatment discontinuation in 47.0%, 22.6%, and 7.5% of patients, respectively. CONCLUSION: Maintenance olaparib demonstrated clinical benefit in patients without a gBRCAm, and across all subgroups, compared with historical placebo controls. There were no new safety signals.
650    _2
$a protein BRCA1 $x genetika $7 D019313
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a epiteliální ovariální karcinom $x farmakoterapie $x genetika $7 D000077216
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zárodečné buňky $7 D005854
650    _2
$a zárodečné mutace $7 D018095
650    _2
$a lidé $7 D006801
650    _2
$a udržovací chemoterapie $7 D060046
650    _2
$a mutace $7 D009154
650    12
$a lokální recidiva nádoru $x farmakoterapie $x genetika $7 D009364
650    12
$a nádory vaječníků $x farmakoterapie $x genetika $7 D010051
650    12
$a ftalaziny $x škodlivé účinky $7 D010793
650    12
$a piperaziny $x škodlivé účinky $7 D010879
650    _2
$a platina $x terapeutické užití $7 D010984
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lheureux, S $u Princess Margaret Hospital, Department of Medical Oncology, Toronto, ON, Canada
700    1_
$a Colombo, N $u University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Cibula, D $u General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lindemann, K $u Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
700    1_
$a Weberpals, J $u Ottawa Hospital Research Institute, Ottawa, ON, Canada
700    1_
$a Bjurberg, M $u Skåne University Hospital, Lund University, Lund, Sweden
700    1_
$a Oaknin, A $u Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
700    1_
$a Sikorska, M $u Olsztyn Provincial Specialist Hospital, Olsztyn, Poland
700    1_
$a González-Martín, A $u Program in Solid Tumors, Center for Applied Medical Research (CIMA) and Clinica Universidad de Navarra, Madrid, Spain
700    1_
$a Madry, R $u Medical University Karol Marcinkowski, Poznań, Poland
700    1_
$a Pérez, M J Rubio $u Hospital Universitario Reina Sofía, Córdoba, Spain
700    1_
$a Ledermann, J $u UCL Cancer Institute, University College London and UCL Hospitals, London, UK
700    1_
$a Davidson, R $u AstraZeneca, Cambridge, UK
700    1_
$a Blakeley, C $u AstraZeneca, Cambridge, UK
700    1_
$a Bennett, J $u AstraZeneca, Cambridge, UK
700    1_
$a Barnicle, A $u AstraZeneca, Cambridge, UK
700    1_
$a Škof, E $u Institute of Oncology Ljubljana, Ljubljana, Slovenia
773    0_
$w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 164, č. 3 (2022), s. 498-504
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35063276 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135510 $b ABA008
999    __
$a ok $b bmc $g 1822752 $s 1170527
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 164 $c 3 $d 498-504 $e 20220119 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace